XiaoMi-AI文件搜索系统
World File Search SystemEstimated
马哈拉施特拉邦电力之前的第1页，共308页...
表4-19：双边电力购买，备用购买和委员会批准的2022-23财年的偏差费用。............................................................................. 150 Table 4-20: Sale Outside Licence Area for H1 of FY 2022-23, as submitted by TPC-D .. 151 Table 4-21: Sale Outside Licence Area for 2022-23 as approved by the Commission (Rs.Crore) ................................................................................................................................. 151 Table 4-22: Transmission Charges & MSLDC Charges for FY 2022-23 approved by the Commission (Rs.Crore) .................................................................................................... 152 Table 4-23:Provisional Power Purchase Cost for FY 2022-23 as submitted by TPC-D 153 Table 4-24: Summary of Power Purchase for FY 2022-23 approved by the Commission............................................................................................................................................. 153 Table 4-25: Normative O&M Expenses for FY 2022-23, as submitted by TPC-D ............ 154 Table 4-26: O&M Expenses for FY 2022-23 as approved by the Commission (Rs.Crore) ............................................................................................................................................ 154 Table 4-27: Estimated Capitalisation for FY 2022-23 as submitted by TPC-D (Rs.Crore) ............................................................................................................................................ 155 Table 4-28: Capitalisation for Wires Business & Supply Business for FY 2022-23 approved by the Commission (Rs.Crore) .......................................................................................... 156 Table 4-29: Estimated Depreciation for FY 2022-23, as submitted by TPC-D (Rs.Crore) ............................................................................................................................................ 156 Table 4-30: Depreciation for Wires Business and Supply Business for FY 2022-23 approved by Commission (Rs.Crore) ............................................................................... 157 Table 4-31: Estimated Interest on Long-Term Loan for FY 2022-23 as submitted by TPC- D (Rs.Crore) ...................................................................................................................... 157 Table 4-32: Interest Expenses for FY 2022-23 approved by the Commission (Rs.Crore) ............................................................................................................................................ 158 Table 4-33: Estimated IoWC for FY 2022-23 as submitted by TPC-D (Rs.千万）........ 158
具有政策的全面回收框架...
Figure 14: Estimated capacities of the recycling unit in tonnes per day and tonnes per annum, required over the years ........................................................................................................................................................................................ 31
减少挪威生活方式排放的选项
图1.1：dagens私人klimafotavtrykk for norge。............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ x Figur 1.3: Beregnet 1,5-graders scenario .......................................................................................................................... xiii Figure 3.1: Current Norwegian lifestyle carbon footprint ................................................................................................. 7 Figure 3.2: Shares of the carbon footprint and of physical consumption for personal transport............................. 8 Figure 3.3: Shares of the carbon footprint and physical consumption for nutrition ................................................ 10 Figure 3.4: Shares of the carbon footprint and of physical consumption for consumer goods .............................. 11 Figure 3.5: Shares of the carbon footprint and of physical consumption for housing ............................................. 12 Figure 3.7: Shares of the carbon footprint and of physical consumption for services............................................. 15 Figure 3.8: Lifestyle carbon footprints of an average and a high-consumption lifestyle ......................................... 17 Figure 4.1: Estimated per capita carbon footprint reduction impacts of low-carbon lifestyle options................. 22 Figure 4.2: Carbon footprint emissions (kgCO 2 e/30m 2 ) prevented with the selected options*........................... 25 Figure 5.1: Estimated 1.5°C scenario for current lifestyle carbon footprint ............................................................... 36 Figure 5.2: Estimated 2°C scenario for current lifestyle carbon footprint ................................................................. 37
蛇河管理计划2022-2024套装...
Describe all types of trips offered : Trip type: (1/2 day fishing, scenic, etc ) ______________________________ Price per person or trip : _____________ Put in/Take out: ____________________________________________________________________________ Estimated start/finish time(s): ________________________________________________________________ Stopping locations: ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
GAO-24-106202，医疗补助托管护理：州指导付款的快速支出增长需要增强的监督和透明度
Figure 1: Number of State Directed Payments in Effect in 2022, as of August 2022 6 Figure 2: CMS State Directed Payment Review and Approval Process 9 Figure 3: Estimated Total Spending in 2022 for State Directed Payments, approved by August 2022, by State 12 Figure 4: Federal Share and Nonfederal Share Sources of Medicaid Managed Care State Directed Payments in Effect in 2022 15 Figure 5: Estimated Cost Shifting for State Directed Payments实际上在2022年有效16图6：2022年州有效付款的估计成本转移，按指示付款的大小17图7：使用州提供者税收和联邦资金融资的州指导付款的示例
记录监控的定期报告...
3.1 Estimated exposure .............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. Post-registration exposure (commercial use) ....................................................................................................................................................................................................................................................................................... 关键临床研究功效的结果..................................................................................................................................................................................................................................................................................................................................................................................................................................................... RESULTS OF POST CONCERCIALIZATION EFFICIENCY ....................................................................................................................................................... KTE-C19-110/NCT01166009 ............................................................................................................................................... KT-EU-471-0117 ......................................................................... 15 3.3.3. YES020-011 ........................................................................................................163.1 Estimated exposure ..............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................Post-registration exposure (commercial use) ....................................................................................................................................................................................................................................................................................... 关键临床研究功效的结果..................................................................................................................................................................................................................................................................................................................................................................................................................................................... RESULTS OF POST CONCERCIALIZATION EFFICIENCY ....................................................................................................................................................... KTE-C19-110/NCT01166009 ............................................................................................................................................... KT-EU-471-0117 ......................................................................... 15 3.3.3. YES020-011 ........................................................................................................16Post-registration exposure (commercial use) .......................................................................................................................................................................................................................................................................................关键临床研究功效的结果.....................................................................................................................................................................................................................................................................................................................................................................................................................................................RESULTS OF POST CONCERCIALIZATION EFFICIENCY ....................................................................................................................................................... KTE-C19-110/NCT01166009 ............................................................................................................................................... KT-EU-471-0117 ......................................................................... 15 3.3.3. YES020-011 ........................................................................................................16RESULTS OF POST CONCERCIALIZATION EFFICIENCY .......................................................................................................................................................KTE-C19-110/NCT01166009 ............................................................................................................................................... KT-EU-471-0117 ......................................................................... 15 3.3.3. YES020-011 ........................................................................................................16KTE-C19-110/NCT01166009 ...............................................................................................................................................KT-EU-471-0117 ......................................................................... 15 3.3.3. YES020-011 ........................................................................................................16KT-EU-471-0117 ......................................................................... 15 3.3.3.YES020-011 ........................................................................................................16
低收入家庭能源援助计划块赠款分配计划
CEAP由美国卫生与公共服务部低收入家庭能源援助计划（LIHEAP）BLOCK GRANT资助；但是，在制定该分配计划时，联邦财政年度（FFY）2025的资金水平尚未发布。The estimated budget used in this allocation plan for the operation of LIHEAP for FFY 2025 assumes that the program will be level-funded at the state's LIHEAP base grant FFY 2024 level of $78.4 million, plus $2.0 million in Infrastructure Investment and Jobs Act funding, an estimated $7.7 million in FFY 2024 LIHEAP carryforward funds, and $400,000 in LIHEAP vendor退款，总估计为2025年的FFY预算约为8850万美元。这构成了社会服务部对资金的最佳估计，可以支持LIHEAP BLOCK赠款分配计划（“计划”）。
第40座园艺作物科学家见面（23.05.2024）
MAP) First fruiting height (cm) 99.40 85.24 Number of fruits / plant 52.26 62.80 Average fruit weight (kg) 1.10 1.37 Estimated yield/plant (kg) 57.8 86.0 Estimated yield / ha (t) 170 245 % increase in yield - 33.89% PRSV incidence 45.87 (42.65) 30.76 (33.70) Shelf life （天）6.60 3.40干乳胶产量/水果（G）5.02 6.12 B：C比率1.5 3.8 III。芒果（Mangifera Indica L.）中的施肥计划下的UHDP var。Neelum和Imam Pasand Neelum和Imam Pasand通过受精在100％的RDF中表现出色，其水果/树数量最高（27.82和12.39），产量/树（7.82和6.37 kg）和产量（分别为13.04和10.62 T/HA）。
计量经济学预测气候变化 - 研究
Their success depends upon (see Hendry, 1997 ): (a) there are regularities in the system being modeled; (b) those regularities are informative about the future; (c) the estimated model captures the regularities; yet: (d) excludes irregularities that might swamp regularities.
生物多样性偏移策略，Morava走廊高速公路项目，塞尔维亚
9 High-level next steps ................................................................................. 38 10 References ................................................................................................... 40 11 Appendix 1: Offset feasibility criteria ...................................................... 41 12 Appendix 2 Biodiversity offsets workshop, meeting minutes .............. 44 13 Appendix 3 – Breakdown of estimated Biodiversity Offset Program budget .................................................................................................................. 54